The Bayer China Hemophilia Treatment Center Development Project is a partnership between Bayer Schering Pharmaceuticals and the Chinese Society of Hematology to improve hemophilia care throughout the country.
China currently has six hemophilia treatment centers that are part of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC). These centers will be further developed and strengthened as part of this initiative, the company said.
Michael Mathews, general manager, hematology, Bayer HealthCare Pharmaceuticals, said: “Our passion for improving the lives of people around the world motivated us to step forward with this major funding pledge. But more importantly, the results will help the quality of care to step ahead, giving Chinese people with hemophilia better opportunities to live the lives they choose. We also consider it a privilege and an honor to be supporting the Chinese hemophilia community in this effort.”